CAJ | 학술논문

目的探讨EZH2(enhancer of zeste homolog 2)基因在肿瘤分期和淋巴结转移中的临床意义.方法以50例癌旁肠壁组织(距肿瘤5 cm以上)作为对照组,50例结直肠癌组织作为实验组,用RT-PCR技术分析EZH2基因在结直肠癌及癌旁中的表达情况.结果 (1)EZH2在癌旁组织中的表达阳性率为12%(6/50),而在结直肠癌组织中表达阳性率为84%(42/50),两组比较差异有统计学意义(X~2=49.05,P<0.05);(2)属Dukes A、B期的9例呈EZH2阳性表达,阳性率52.94%(9/17),属Dukes C、D期的33例全部为EZH2阳性表达,阳性率100%(33/33);两组比较差异有统计学意义(X~2=15.15,P<0.005);(3)无淋巴结转移的24例中有17例呈EZH2阳性表达,阳性率为70.83%(17/24);有淋巴结转移的26例中25例呈阳性表达,阳性率为96.15%(25/26); 两组比较差异有统计学意义(X~2=4.219,P＜0.05).结论 EZH2基因的表达对判断结直肠肿瘤的转移机制以及病情进展有一定的临床价值,并提示EZH2基因与肿瘤的侵袭和转移有关.
목적 탐토EZH2(enhancer of zeste homolog 2)기인재종류분기화림파결전이중적림상의의.방법 이50례암방장벽조직(거종류5 cm이상)작위대조조,50례결직장암조직작위실험조,용RT-PCR기술분석EZH2기인재결직장암급암방중적표체정황.결과 (1)EZH2재암방조직중적표체양성솔위12%(6/50),이재결직장암조직중표체양성솔위84%(42/50),량조비교차이유통계학의의(X~2=49.05,P<0.05);(2)속Dukes A、B기적9례정EZH2양성표체,양성솔52.94%(9/17),속Dukes C、D기적33례전부위EZH2양성표체,양성솔100%(33/33);량조비교차이유통계학의의(X~2=15.15,P<0.005);(3)무림파결전이적24례중유17례정EZH2양성표체,양성솔위70.83%(17/24);유림파결전이적26례중25례정양성표체,양성솔위96.15%(25/26); 량조비교차이유통계학의의(X~2=4.219,P＜0.05).결론 EZH2기인적표체대판단결직장종류적전이궤제이급병정진전유일정적림상개치,병제시EZH2기인여종류적침습화전이유관.
Objective To Analyze the expression of EZH2 in colorectal cancer and its clinical significance in colorectal cancer cell differentiation, staging and metastasis. Methods Fifty tissue specimens of colorectal cancer and their adjacent normal tissue specimens (more than 5 cm from the tumor) were assigned as experimental group and control group, respectively. RT-PCR was used for analysis of EZH2 expression. Results (1)The rates of EZH2 expression were 12%(6/50) and 85%(42/50) in control group and experimental group, respectively (X~2 = 49.05, P<0.005). (2)In 17 cases of Dukes stage A and B, positive expression rate of EZH2 was 52.94% (9/17), while it was 100% (33/33) in cases of Duke C and D(X~2＝15.15,P<0.005).(3)The rates of EZH2 expression wese 96.15%(25/26) and 70.83(17/24) in cases with and without mesenteric lymph node gene can be applied for determining the progression of colorectal cancer. Furthermore, the EZH2 may involve in the invasion and metastasis of cancer cell.